Relationships among neurocognitive status, medication adherence measured by pharmacy refill records, and virologic suppression in HIV-infected persons

Journal of Acquired Immune Deficiency Syndromes

Volumn 62, Issue 3, 2013, Pages 282-292

  Andrade, Adriana S A ^a   Deutsch, Reena ^b   Celano, Shivaun A ^a   Duarte, Nichole A ^b   Marcotte, Thomas D ^b   Umlauf, Anya ^b   Atkinson, J Hampton ^b,c   McCutchan, J Allen ^b   Franklin, Donald ^b   Alexander, Terry J ^b   Mcarthur, Justin C ^a   Marra, Christina ^d   Grant, Igor ^b   Collier, Ann C ^d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Adherence; Cognitive impairment; CPE; HAND; HIV; Pharmacy refill records

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; VIRUS RNA;

ADULT; AGE; ANTIVIRAL THERAPY; ARTICLE; BLOOD LEVEL; CEREBROSPINAL FLUID; COGNITION; COMORBIDITY; DISEASE DURATION; EDUCATIONAL STATUS; ETHNIC DIFFERENCE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MENTAL DISEASE; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PHARMACY REFILL RECORD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM; SELF REPORT; SEX DIFFERENCE; STATISTICAL MODEL; SUBSTANCE ABUSE; TREATMENT DURATION; VIRUS INHIBITION; VIRUS LOAD; WORKING MEMORY;

EID: 85028122648     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31827ed678     Document Type: Article

References (51)

1. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of low nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997;337:725-733.
2. Sacktor N, Lyles RH, Skolasky R, et al. HIV-associated neurologic disease incidence changes: multicenter AIDS Cohort Study, 1990- 1998. Neurology. 2001;56:257-260.
3. Sterne JA, May M, Costagliola D, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009;373: 1352-1363.
4. Bartlett JA. Addressing the challenges of adherence. J Acquir Immune Defic Syndr. 2002;29(suppl 1):2-10.
5. Chesney MA. The elusive gold standard. Future perspectives for HIV adherence assessment and intervention. J. Acquir Immune Defic Syndr. 2006;43(suppl 1):149-155.
6. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30.
7. Raffa JD, Tossonian HK, Grebely J, et al. Intermediate highly active antiretroviral therapy adherence thresholds and empirical models for the development of drug resistance mutations. J Acquir Immune Defic Syndr. 2008;47:397-399.
8. Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001; 15:1181-1183.
9. Bartlett JA, DeMasi R, Quinn J, et al. Overview of the effectiveness of triple combination therapy in antiretroviral-naïve HIV-1 infected adults. AIDS. 2001;15:1369-1377.
10. Ammassari A, Murri R, Pezzotti P, et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr. 2001;28:445-449.
11. Wagner GJ, Goggin K, Remien RH, et al. A closer look at depression and its relationship to HIV antiretroviral adherence. Ann Behav Med 2011; 42:352-360.
12. Lucas GM. Substance abuse, adherence with antiretroviral therapy, and clinical outcomes among HIV-infected individuals. Life Sci. 2011;88: 948-952.
13. Barfod TS, SØrensen HT, Nielsen H, et al. "Simply forgot" is the most frequently stated reason for missed doses of HAART irrespective of degree of adherence. HIV Med 2006;7:285-290.
14. Senkomago V, Guwatudde D, Breda M, et al. Barriers to antiretroviral adherence in HIV-positive patients receiving free medication in Kayunga, Uganda. AIDS Care. 2011;23:1246-1253.
15. Heaton RK, Clifford DB, Franklin DR Jr, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. 2010;75:2087-2096.
16. Robertson DR, Smurzynski M, Parsons TD, et al. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS. 2007; 21:1915-1921.
17. Grant I, Atkinson JH, Hesselink JR, et al. Evidence for early central nervous system involvement in the acquired immunodeficiency syndrome (AIDS) and other human immunodeficiency virus (HIV) infections. Studies with neuropsychologic testing and magnetic resonance imaging. Ann Intern Med 1987;107:828-836.
18. Andrade AS, McGruder HF, Wu AW, et al. A programmable prompting device improves adherence to highly active antiretroviral therapy in HIV-infected subjects with memory impairment. Clin Infect Dis. 2005; 41:875-882.
19. Lovejoy TI, Suhr JA. The relationship between neuropsychological functioning and HAART adherence in HIV-positive adults: a systematic review. J Behav Med 2009;32:389-405.
20. Hinkin CH, Castellon SA, Durvasula RS, et al. Medication adherence among HIV+ adults. Neurology. 2002;59:1944-1950.
21. Barclay TR, Hinkin CH, Castellon SA, et al. Age-associated predictors of medication adherence in HIV-positive adults: health beliefs, self-efficacy, and neurocognitive status. Health Psychol. 2007;26:40-49.
22. Woods SP, Dawson MS, Weber E, et al. Timing is everything: antiretroviral nonadherence is associated with impairment in time-based prospective memory. J Int Neuropsychol Soc. 2009;15:42-52.
23. Zogg JB, Woods SP, Sauceda JA, et al. The role of prospective memory in medication adherence: a review of an emerging literature. J Behav Med 2012;35:47-62.
24. Ettenhofer ML, Foley J, Castellon SA, et al. Reciprocal prediction of medication adherence and neurocognition in HIV/AIDS. Neurology. 2010;74:1217-1222.
25. Becker BW, Thames AD, Woo E, et al. Longitudinal change in cognitive function and medication adherence in HIV-infected adults. AIDS Behav. 2011;15:1888-1894.
26. Simoni JM, Kurth AE, Pearson CR, et al. Self-report measures of antiretroviral therapy adherence: a review with recommendations for HIV research and clinical management. AIDS Behav. 2006;10:227-245.
27. Kitahata MM, Reed SD, Dillingham PW, et al. Pharmacy-based assessment of adherence to HAART predicts virologic and immunologic treatment response and clinical progression to AIDS and death. Int J STD AIDS. 2004;15:803-810.
28. Grossberg R, Gross R. Use of pharmacy refill data as a measure of antiretroviral adherence. Curr HIV/AIDS Rep. 2007;4:187-191.
29. Bisson GP, Gross R, Bellamy S, et al. Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy. PLoS Med 2008;5:e109.
30. El-Khatib A, Katzenstein D, Marrone G, et al. Adherence to drug-refill is a useful early warning indicator of virologic and immunologic failure among HIV patients on first-line ART in South Africa. PLoS One. 2011; 6:e17518.
31. Carey CL, Woods SP, Gonzalez R, et al. Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. J Clin Exp Neuropsychol. 2004;26:307-319.
32. Heaton RK, Grant I, Butters N, et al. The HNRC 500-Neuropsychology of HIV infection at different stages. J Internat Neuropsychol Soc. 1995;1: 231-251.
33. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69:1789-1799.
34. Hollingshead AB, Redlich FC. Social Class and Mental Illness: A Community Study. New York, NY: John Wiley; 1958.
35. World Health Organization. Composite International Diagnostic Interview, Version 2.1. Geneva, Switzerland: WHO; 1997.
36. Beck AT, Steer RA, Brown GK. Beck Depression Inventory-Second Edition Manual. San Antonio, TX: The Psychological Corporation; 1996.
37. Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008;65: 65-70.
38. Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. AIDS Care. 2000;12:255-266.
39. Zar JH. Biostatistical Analysis. 3rd ed. Upper Saddle River, NJ: Prentice Hall; 1996:282.
40. Barnett AG, van der Pols JC, Dobson AJ. Regression to the mean: what it is and how to deal with it. Int J Epidemiol. 2005;34:215-220.
41. Hinkin CH, Hardy DJ, Mason KI, et al. Medication adherence in HIVinfected adults: effect of patient age, cognitive status, and substance abuse. AIDS. 2004;18(suppl 1):S19-S25.
42. Levine AJ, Hinkin HC, Castellon SA, et al. Variations in patterns of highly active antiretroviral therapy (HAART) adherence. AIDS Behav. 2005;9:355-362.
43. Solomon TM, Halkitis PN. Cognitive executive functioning in relation to HIV medication adherence among gay, bisexual, and other men who have sex with men. AIDS Behav. 2008;12:68-77.
44. Contardo C, Black AC, Beauvais J, et al. Relationship of prospective memory to neuropsychologic function and antiretroviral adherence. Arch Clin Neuropsychol. 2009;24:547-554.
45. Martin EM, Pitrak DL, Weddington W, et al. Cognitive impulsivity and HIV serostatus in substance dependent males. J Int Neuropsychol Soc. 2004;10:931-938.
46. Heaton RK, Marcotte TD, Mindt MR, et al. The impact of HIVassociated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc. 2004;10:317-331.
47. Puskas CM, Forrest JI, Parashar S, et al. Women and vulnerability to HAART non- adherence: a literature review of treatment adherence by gender from 2000 to 2011. Curr HIV/AIDS Rep. 2011;8:277-287.
48. Glesby MJ, Hoover DR. Survivor treatment selection bias in observational studies: examples from the AIDS literature. Ann Intern Med 1996; 124:999-1005.
49. Cysique LA, Vaida F, Letendre S, et al. Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology. 2009;73:342-348.
50. Bickel WK, Yi R, Landes RD, et al. Remember the future: working memory training decreases delay discounting among stimulant addicts. Biol Psychol. 2011;69:260-265.
51. Woods SP, Weber E, Cameron MV, et al. Spontaneous strategy use protects against visual working memory deficits in older adults infected with HIV. Arch Clin Neuropsychol. 2010;25:724-733.